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ABSTRACT 
We describe a case of toxic epidermal necrolysis after 
intranasal application of mupirocin in a 76-year-old woman. The 
drug was given for eradication of methicillin-resistant 
Staphylococcus aureus (Infect Control Hosp Epidemiol 
2003;24:459-460). 
Toxic epidermal necrolysis (TEN) is characterized 
by an erythemato-bullous skin eruption followed by epi-
dermal necrolysis with skin scaling and mucosal involve-
ment. The general consequences are extended burns. 
Mortality is approximately 20% to 30%, increasing with age 
and the extent of the lesions.12 The most severe compli-
cations are sepsis and ocular involvement. The mecha-
nisms responsible for the accelerated apoptosis of the ker-
atinocytes remain unclear, but, besides multiple factors, 
drugs are clearly implicated. Many agents are deemed 
responsible for TEN. Among the most frequently cited are 
nonsteroidal anti-inflammatory drugs, sulfonamides, and 
anticonvulsants.3 Until now, TEN occurring after topical 
intranasal applications of mupirocin has never been 
described. 
CASE REPORT 
A 76-year-old woman with a tracheostomy after opera-
tion for an oropharyngeal carcinoma was admitted to our 
hospital for ventilatory weaning. Her usual medications 
were prednisone, ipratropium bromide, salbutamol, citalo-
pram, hydrochlorothiazide, lisinopril, aspirin, and aceta-
minophen. She had been treated with the same medication 
regimen for several weeks before entering our hospital. 
She was allergic to penicillin and had asthma. 
Eighteen days later, sputum cultures yielded methi-
cillin-resistant Staphylococcus aureus. The patient was 
isolated, bathed with chlorhexidine once a day, and treat-
ed with mupirocin intranasally twice a day. Two days 
later, a skin eruption of a maculo-erythematous type 
appeared around the nares, evolving rapidly into bullae 
and extending to the cheeks and neck, accompanied by 
a fever (temperature, 38°C and higher). The patient had 
been given two baths with chlorhexidine and four 
intranasal applications of mupirocin before the onset of 
the rash. Despite the discontinuation of intranasal 
mupirocin and the chlorhexidine baths, the skin lesions 
progressed in the form of large bullae involving the face 
and upper trunk, covering approximately 20% of the body 
surface area. A positive Nikolsky sign confirmed the 
clinical diagnosis of TEN. With the consent of the 
patient, considering her dismal oncologic prognosis and 
bedridden state, no life support was started. Five days 
after the eruption of the dermal lesions, the patient died 
of sepsis. 
DISCUSSION 
In this patient, TEN appeared after the application of 
mupirocin for eradication of methicillin-resistant S. 
aureus. It is highly probable that mupirocin, introduced 2 
days before the appearance of the skin disease, was the 
cause because, except for chlorhexidine skin antisepsis 
given at the same time, no other medication had been 
introduced during the 4 preceding weeks. In particular, 
acetaminophen, often cited as a cause of TEN,4 had been 
given for many weeks for the patient's chronic pain due to 
the oropharyngeal carcinoma. The cutaneous application 
of chlorhexidine has been followed by anaphylactoid and 
immediate or delayed skin reactions of eczematous or 
urticarial type, but has never been implicated as a cause 
of bullous lesions.5,6 Mupirocin is usually well tolerated, 
but can occasionally induce burn-type lesions, rash, 
edema, and exudation.7 
In 1987, Daly reported a case of vesicular dermatitis 
following the topical administration of mupirocin in a 
patient suffering from a chronic stasis dermatitis.8 
Mupirocin contains polyethylene glycol as an excipient, a 
product well known for its allergenic properties.8"10 In our 
case, however, mupirocin for nasal use contained no poly-
ethylene glycol, which is ill tolerated by the mucosal sur-
faces (ie, causing irritation, dryness, and pruritus), but 
did contain paraffin and glycerin esters. 
Our patient developed TEN 48 hours after topical 
intranasal applications of mupirocin. It seems reason-
able to imply a highly probable relationship between 
TEN and the application of mupirocin, although such a 
phenomenon has never been described in the literature. 
Our patient was atopic, with an allergy to penicillin, and 
was suffering from asthma; she also had damaged facial 
skin and nasal mucosa due to former intubation and the 
presence of a nasogastric suction tube. All of these ele-
ments might have enhanced a hypersensitivity reaction 
to the nasal application of mupirocin, provoking TEN. 
Except for a re-exposure trial, one can never be cer-
tain that a drug is responsible for TEN. Nevertheless, 
many arguments seem to corroborate the hypothesis that 
mupirocin was indeed implicated in the TEN of this 
patient. 
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AB STRACT 
Methicillin-resistant Staphylococcus aureus (MRSA) has tra-
ditionally been a nosocomial pathogen. However, several recent 
studies have noted community-acquired MRSA among young, 
healthy patients with no risk factors or healthcare system expo-
sure. We report the transmission of a strain of community-
acquired MRSA in our neonatal intensive care unit (Infect Control 
Hosp Epidemiol 2003;24:460-461). 
Staphylococcus aureus is a major cause of nosocomi-
al and community-acquired infections. Since the first 
report of methicillin-resistant Staphylococcus aureus 
(MRSA) in I960,1 MRSA has spread throughout the 
world. Traditionally, MRSA infections have been 
acquired almost exclusively in hospitals, long-term-care 
facilities, and similar institutional settings. When cases of 
MRSA infection have been identified in the community, 
investigation usually reveals prior contact with the 
healthcare system such as a history of recent hospitaliza-
tion, close contact with a person who has been hospital-
ized, or other risk factors such as previous antimicrobial 
drug therapy.23 We report transmission of an isolate of 
community-acquired MRSA in our neonatal intensive 
care unit. 
CASE REPORT 
A 22-year-old pregnant African American woman 
was admitted to our hospital with a history of prolonged 
rupture of membranes for 6 days and for chorioamnioni-
tis. The patient had no prior history of hospitalization, 
surgery, work or residence in a long-term-care facility, or 
injection drug use. She underwent a primary transverse 
cesarean section on the day of admission because of 
arrest of dilatation. The patient received ampicillin for 
group B Streptococcus prophylaxis. The neonate born was 
admitted to the neonatal intensive care unit with an 
Apgar score of 6 after 5 minutes, a body temperature of 
39° C, and the need for oxygen. The blood cultures per-
formed for the neonate on the first day of life were posi-
tive for MRSA and Enterococcus faecalis. The mother was 
given clindamycin and gentamicin due to extensive blood 
loss and fever, which were changed after 24 hours to 
metronidazole and levofloxacin due to acute renal failure. 
The fever did not resolve and blood cultures performed 
for the mother on the second day of admission were pos-
itive for MRSA. The two isolates were sensitive only to 
gentamicin, rifampicin, and vancomycin. The mother and 
neonate were each treated with vancomycin and 
responded well to therapy. 
Routine weekly surveillance cultures for MRSA in 
the neonatal intensive care unit 7 days after the admission 
of the neonate revealed nasal MRSA colonization in a dif-
ferent neonate who had been admitted to the NICU 3 
weeks previously. Surveillance cultures of this second 
neonate had been negative prior to the admission of the 
neonate with MRSA sepsis. 
RESULTS 
Pulsed-field gel electrophoresis (PFGE) was per-
formed after digestion with Smal on MRSA isolates of all 
three patients. All strains had an identical PFGE banding 
pattern, suggesting one clonal PFGE subtype (Figure). 
This PFGE pattern differed significantly from that of 
MRSA strains previously recovered in the neonatal inten-
sive care unit or adult inpatient areas of our hospital. Our 
findings suggest transmission of community-acquired 
MRSA in the neonatal intensive care unit. 
D I S C U S S I O N 
The SENTRY Antimicrobial Surveillance Program 
found an increase of MRSA among both nosocomial and 
community-onset strains (from 34% in 1997 to 45% in 1999 
for nosocomial MRSA, and from 21% in 1997 to 27% in 
1999 for community-acquired MRSA) in the United 
States.4 The increase in community-acquired MRSA 
infections among patients admitted to hospitals has the 
potential to increase the prevalence and risk of nosoco-
mial infections due to MRSA.5 Patients with community-
acquired MRSA likely have not had prior contact with the 
healthcare system, and therefore may not be suspected 
of having MRSA infection or colonization. This may 
result in a delay of the implementation of contact isola-
tion precautions for MRSA as recommended by the 
Centers for Disease Control and Prevention.6 
The mother had had prior contact with the health-
care system due to prenatal care. More detailed question-
ing after the result of the blood culture was known also 
revealed that she had been caring for an individual with a 
chronic wound infection. Whether that individual was 
MRSA positive remained unknown. Considering the 
antimicrobial susceptibility pattern of the strain and the 
PFGE result, it seems possible that the strain was acquired 
from the individual with the chronic wound infection. 
The impact on the number of nosocomial MRSA 
infections in a particular hospital will be influenced by 
the prevalence of MRSA acquisition in the community, 
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